Blood
Articles in this Issue
Enhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF
Abstract The half-life of recombinant human von Willebrand factor (rVWF) expressed in CHO cells (CHO-rVWF; Vonicog alfa; and Vonvendi/Veyvondi) is significantly longer than that of p...
Classic Hodgkin lymphoma in the cerebellum: a rare site for a common disease
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL
Abstract Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial resulted in superior progressi...
Getting to the root of high-risk leukemias
Exploiting tumor-derived IL-10 activity in lymphoma therapy
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
Abstract Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that is associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective st...
Burkitt lymphoma: click here to add to CAR-T?
Novel regulators of GVHD revealed through microbiome and metabolome patterns across distinct intestinal regions
Abstract Microbial dysbiosis and metabolite changes in the gastrointestinal (GI) tract have been linked to pathogenesis and severity of many diseases, including graft-versus-host dis...
The advent of multiomics in experimental transplantation
MURANO’s final conclusions: what we’ve learned, what’s next?
A great mitigator of non-ICANS neurotoxicities?
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment
Abstract Potentially fatal non-immune effector cell–associated neurotoxicity syndrome neurotoxicities (NINTs) after B-cell maturation antigen–targeted chimeric antigen receptor (CAR)...
Immunoactinopathies revisited: understanding clinical manifestations and biological pathways
Abstract Immune cell functionality is highly dependent on the actin cytoskeleton. The actin cytoskeleton is regulated by a complex molecular machinery that involves multiple genes. M...
STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALL
Abstract We used single-cell genomics to characterize a patient with T-cell acute lymphoblastic leukemia treated in the Children’s Oncology Group AALL0434 trial with poor clinical ou...
Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?
Abstract Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for patients with chronic myeloid leukemia. The standard dose has been established for each drug according to...
The sweet business of VWF clearance
IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy
Abstract The contribution of interleukin-10 (IL-10), secreted by tumoral B cells, to the progression and shaping of the microenvironment in diffuse large B-cell lymphoma (DLBCL) with...
Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome
Abstract The critical role of leukemia-initiating cells as a therapy-resistant population in myeloid leukemia is well established. However, the molecular signatures of such cells in...